Accession Therapeutics Limited
Lok Hang Mak currently holds the position of Associate Director at Accession Therapeutics Limited, a role commenced in July 2022. Previously, Lok Hang Mak served as Associate Director of Antibody Discovery and Engineering at Immunocore from November 2014 to August 2022, where responsibilities also included positions as Principal Scientist, Senior Scientist - Manager, and Senior Scientist. Prior experience includes a research associate role at Imperial College London from April 2009 to October 2014.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.